4D Pharma plc Announces First Patient Enrolment in Blautix IBS Phase II study
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, announces the randomisation of the first patient in a Phase II clinical trial of Blautix in patients with Irritable Bowel Syndrome […]
